Q-omics provides the consensus-scored APOA5 profile across patient tissues and cancer cell-line models. APOA5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, APOA5 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, APOA5 protein abundance shows 9,432 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight ACC, LUAD, and CCRCC as cancer lineages where APOA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for APOA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes APOA5 survival associations across molecular data types. APOA5 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible APOA5 RNA expression–survival associations across cancer types. High APOA5 expression shows unfavorable associations in ACC, BRCA, DLBC and CHOL, but favorable associations in MESO and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for APOA5 RNA expression.
This table summarizes APOA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for APOA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. APOA5 shows lower tumor expression in LUAD, THCA, LUSC, CHOL and LIHC and higher tumor expression in UCEC. The LUAD box plot shows higher APOA5 RNA expression in normal versus tumor tissue (log2 FC = −0.436, t-test p < 0.001).
This table shows molecular features associated with APOA5 in patient tissues and cancer cell lines. In patient samples, APOA5 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, APOA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
